Stevanato Group SPA (Stevanato Group SPA) LT-Debt-to-Total-Asset : 0.13 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Stevanato Group SPA's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.13.

Stevanato Group SPA's long-term debt to total assets ratio increased from Mar. 2023 (0.08) to Mar. 2024 (0.13). It may suggest that Stevanato Group SPA is progressively becoming more dependent on debt to grow their business.

Stevanato Group SPA LT-Debt-to-Total-Asset Historical Data

The historical data trend for Stevanato Group SPA's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA LT-Debt-to-Total-Asset Chart

Stevanato Group SPA Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.35

0.30

0.14

0.09

0.12

Stevanato Group SPA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													0.08	0.07	0.10	0.12	0.13

Stevanato Group SPA LT-Debt-to-Total-Asset Calculation

Stevanato Group SPA's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	278.245	/	2259.081
	=	0.12

Stevanato Group SPA's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	304.93	/	2405.15
	=	0.13

Stevanato Group SPA (NYSE:STVN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Stevanato Group SPA LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Stevanato Group SPA (Stevanato Group SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

87N:Germany

Address

Via Molinella 17, Piombino Dese, Padua, ITA, 35017

Website

https://www.stevanatogroup.com

Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.